摘要
MicroRNA-153 (miR-153)被认为是肿瘤调节器。miR-153表达沉默诱导乳腺癌细胞凋亡。数据表明,miR-153的水平上调通过PTEN或FOXO1的表达下调促进细胞增殖,从而抑制癌细胞的增殖。本研究旨在确定miR-153对化疗和肝癌细胞中靶向药物的作用并研究相关机制。采用MTT法、软琼脂、反式和流式细胞仪分析法检查miR-153是否降低了化疗和靶向药物(肝癌细胞中的索拉非尼,足叶乙苷和紫杉醇)的作用。本研究计算了细胞增殖抑制率,相对存活率和每种药物的IC50值。运用免疫印迹和荧光素酶化验进行评估miR-153是否调节与细胞增殖、凋亡或存活有关的重要基因的表达。结果表明:miR-153减弱依托泊苷、紫杉醇和索拉非尼对HepG2细胞的影响;其IC50 值增加分别为从0.25±0.01μmol/L到 1.02±0.14μmol/L、从0.05±0.01μmol/L 到 0.14±0.02μmol/L 和从1.09±0.15μmol/L 到5.18±0.99μmol/L。 此外,mir-153还减少了这些药物对MHCC-97 H、MHCC-97 L和L-02细胞的作用;同时也减少了索拉非尼、依托泊苷和紫杉醇对HepG2细胞不依赖锚定生长的影响。miR-153的过度表达降低依托泊苷和紫杉醇在HepG2细胞的细胞周期阻滞中的活性并降低索拉非尼对肝癌细胞的侵袭和迁移的作用。此外, miR-153过度表达也增强HepG2、MHCC-97H、MHCC-97 L 和L-02细胞的生长。机制数据显示, miR-153过表达可下调荧光素酶报告载体、p15-Luc和p21-Luc的活性;增强促生存或抗凋亡蛋白Survivin和BCL-2的水平。这些结果表明,miR-153的过表达通过多重机制保护HepG2 细胞系对抗这些药物的作用,而miR-153在未来的肝癌诊断和治疗干预中可能是一个新的靶点。
关键词: 依托泊苷,肝癌细胞,miR-153,PTEN,紫杉醇,索拉非尼。
图形摘要
Current Cancer Drug Targets
Title:MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells
Volume: 15 Issue: 3
Author(s): Yan Chen, Fan Feng, Xudong Gao, Chunping Wang, Huiwei Sun, Cuihong Zhang and Zhen Zeng, Yinying Lu, Linjing An, Jianhui Qu, Fusheng Wang and Yongping Yang
Affiliation:
关键词: 依托泊苷,肝癌细胞,miR-153,PTEN,紫杉醇,索拉非尼。
摘要: MicroRNA-153 (miR-153) is considered to be a tumor regulator. Silencing of miR-153 expression induced apoptosis in breast cancer cells. Data on mechanism suggest that up-regulation of miR- 153 level promotes cell proliferation via the down regulation of the expression of PTEN or FOXO1, which attenuates the proliferation of cancerous cells. This study aims to identify the effect of miR-153 on the activity of chemotherapeutic and targeted agents in HCC cells and to investigate the mechanisms involved. MTT, soft agar, trans-well and flow cytometry assays were performed to examine whether miR-153 down-regulated the activity of the chemotherapeutic and targeted drugs, Sorafenib, Etoposide and Paclitaxel in HCC cells. The rate of proliferation inhibition, relative survival rates and IC50 values of each drug were calculated. Western blot and luciferase assays were performed to assess whether miR-153 modulates the expression of important genes related to cell proliferation, apoptosis or survival. Results showed that miR-153 attenuated the effect of Etoposide, Paclitaxel and Sorafenib on HepG2 cells; the IC50 value increased from 0.25±0.01μmol/L to 1.02±0.14μmol/L, 0.05±0.01μmol/L to 0.14±0.02μmol/L and from 1.09±0.15μmol/L to 5.18±0.99μmol/L, respectively. In addition, miR-153 also reduced the effect of these drugs on MHCC- 97H, MHCC-97 L and L-02 cells; and it also reduced the effects of Sorafenib, Etoposide and Paclitaxel on anchorindependent growth of HepG2 cells. Over-expression of miR-153 down-regulated the activity of Etoposide and Paclitaxel on cell cycle arrest of HepG2 cells and the effect of Sorafenib on the invasion and migration of HepG2 cells. Furthermore, overexpression of miR-153 also enhanced the growth of HepG2, MHCC-97H, MHCC-97 L and L-02 cells. Mechanisms data showed that overexpression of miR-153 down regulated the activity of luciferase reporters, p15-Luc and p21-Luc; and enhanced the protein level of pro-survival or anti-apoptosis proteins Survivin and BCL-2. These results show that overexpression of miR-153 protects HepG2 cells against the effects of these drugs via multiple mechanisms, and miR-153 may be a novel target for HCC in future diagnostic and therapeutic interventions.
Export Options
About this article
Cite this article as:
Yan Chen, Fan Feng, Xudong Gao, Chunping Wang, Huiwei Sun, Cuihong Zhang and Zhen Zeng, Yinying Lu, Linjing An, Jianhui Qu, Fusheng Wang and Yongping Yang , MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells, Current Cancer Drug Targets 2015; 15 (3) . https://dx.doi.org/10.2174/1568009615666150225122635
DOI https://dx.doi.org/10.2174/1568009615666150225122635 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets Unraveling Progesterone-Induced Molecular Mechanisms in Physiological and Pathological Conditions
Current Clinical Pharmacology Pyrimidinone Associated Triazole Carboxamides: Synthesis, Characterization, Cytotoxicity and DNA Binding Studies
Current Bioactive Compounds Thyroid Hormone-Induced Angiogenesis
Current Cardiology Reviews Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Development of Structure Activity Correlation Model on Azetidin-2-ones as Tubulin Polymerization Inhibitors
Letters in Drug Design & Discovery Lysophospholipids: Synthesis and Biological Aspects
Current Organic Chemistry Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology UPA and PAI-1 Analysis from Fixed Tissues – New Perspectives for a Known Set of Predictive Markers
Current Medicinal Chemistry Histone Deacetylase Inhibitors In Inflammatory Disease
Current Topics in Medicinal Chemistry Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking
Current Immunology Reviews (Discontinued) Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Current Medicinal Chemistry Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Strategies for In Vivo siRNA Delivery in Cancer
Mini-Reviews in Medicinal Chemistry Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics